# Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)

> **NIH NIH UM1** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2020 · $451,484

## Abstract

PROJECT SUMMARY
Establishment of New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) is proposed in
response to RFA-AI-18-046 entitled “Vaccine and Treatment Evaluation Units (VTEUs) (UM1 Clinical Trial
Required)”. NYU VTEU will be one of the 10 fixed sites that will participate in the NIAID Infectious Diseases
Clinical Research Consortium (IDCRC). Within the consortium, this NYU VTEU will work closely with NIAID, the
Leadership Group (LG), other VTEUs, and NIAID-supported research resources.
The broad, long-term objective of NYU VTEU is to protect and restore human health through clinical trials of
innovative medical countermeasures to combat microbial threats. While major advances in vaccines and
antimicrobial agents have resulted in large reductions in morbidity and mortality, emerging and re-emerging viral
threats (e.g., Ebola, Zika, SARS, MERS, Nipah, dengue) and widespread antimicrobial drug resistance threaten
to reverse these gains. Furthermore, we remain without broadly effective vaccines against the major infectious
disease killers: tuberculosis, malaria, and AIDS. A better seasonal influenza vaccine and ultimately a universal
influenza vaccine are needed, as evidenced by 80,000 US flu deaths during the 2017-18 season. Working with
NIAID and LG, NYU VTEU will review, refine and implement the infectious diseases clinical research agenda.
As per RFA-AI-18-046, the initial IDCRC priority research areas include: sexually transmitted infections (STIs),
malaria and neglected tropical diseases, respiratory infections, enteric diseases, and emerging infections. The
medical countermeasures to be studied include: vaccines, biologics, therapeutics, biomarkers with predictive
value, devices, and diagnostics.
NYU VTEU team has extensive expertise and experience with these priority infectious diseases and
countermeasures. When high priority pathogens need to be addressed quickly, NYU VTEU has demonstrated
experience in rapid responsiveness and surge capacity - critical elements of the optimal VTEU. Importantly, in
order to speed the development of needed vaccines, an inpatient research unit for controlled human infection
model (CHIM) studies has been developed at NYU VTEU. NYU School of Medicine comprises seven major
hospitals. The diverse patients cared for in these hospitals and associated clinics (8.4 million outpatient visits
and 144,000 inpatient admissions in 2018), along with the large diverse NYC population of 8.6 million (largest
city in US), are ideal for recruitment of patients with specific conditions and healthy individuals.

## Key facts

- **NIH application ID:** 9873567
- **Project number:** 1UM1AI148574-01
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Mark Joseph Mulligan
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $451,484
- **Award type:** 1
- **Project period:** 2020-04-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9873567

## Citation

> US National Institutes of Health, RePORTER application 9873567, Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) (1UM1AI148574-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9873567. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*